Among patients who discontinued enfortumab vedotin due to an ongoing response or toxicity, 57% were treatment-free and alive 1 year later.
Joy Li, MD
Advertisement
Articles by Joy Li, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer
2
Navigating ctDNA-Guided Decision-Making in Muscle-Invasive Bladder Cancer
3
Prophylactic Cranial Irradiation Improves Survival in Limited-Stage SCLC
4
Clinical Implications of Earlier CAR-T Therapy in Relapsed/Refractory Multiple Myeloma
5